Navigation Links
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Stifel Nicolaus Healthcare Conference on Friday, September 9, 2011 at 10:55 a.m. EDT (7:55 a.m. PDT).  The conference is being held at the Four Seasons Hotel in Boston.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, setrobuvir and ANA773.

Dr. Worland will also present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13, 2011 at 9:35 a.m. EDT (6:35 a.m. PDT).  The conference is being held at the Waldorf=Astoria Hotel in New York City.  

Each presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software.  A replay of the presentations will be available approximately one hour after the live webcasts conclude and will be available through September 23, 2011 and September 27, 2011, respectively.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is conducting a Phase IIb study of setrobuvir, the Company's DAA, added to pegylated interferon and ribavirin for the treatment of hepatitis C.  The Company is also developing ANA773, the Company's oral, small-molecule
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
3. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
5. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
6. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a ... that are used solely in scientific experiments, is currently ... years in business, Maxim Peptide, which was created by ... a new and updated website that now features a ... has been updated with fascinating articles about peptide research, ...
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... GENEVA , July 11, 2014 ... pleased to announce the appointment of John P. ... Campus Biotech   in  Geneva . ... on Campus Biotech in Geneva , ... internationally recognised neuroscientists. John P. Donoghue , founder ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3
... School of Economics and Political Science (LSE), Chatham ... on Emerging Nanotechnologies (PEN), an initiative of Woodrow ... Charitable Trusts, have been awarded a $587,000 European ... on regulating nanotechnologies in the European Union and ...
... Prevent HIV from Replicating, GAITHERSBURG, Md., Feb. ... gene therapies for HIV and genetic,diseases, presented results ... gene,therapy for the treatment of AIDS, at the ... in Boston, MA., "This appears to be ...
... Novavax, Inc. (Nasdaq:,NVAX) a clinical-stage vaccine company, ... Executive Officer, will be presenting at the,BIO CEO ... 12, 2008 at the,Waldorf=Astoria Hotel in New York. ... strategy, research and development progress. A link to ...
Cached Biology Technology:European Commission gives grant to investigate transatlantic oversight of nanotech 2European Commission gives grant to investigate transatlantic oversight of nanotech 3VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
(Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
(Date:7/10/2014)... , July 3, 2014 Research ... addition of the "Global Gesture Recognition & ... - Forecasts to 2020" report to their ... Global Gesture Recognition & Touch-Less Sensing Market ... around for a while, but the companies were ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... 21 researchers from 11 nations, including professor Robert "JJ" Orth ... first-ever study of the risk of extinction for individual seagrass ... the International Union for the Conservation of Nature (IUCN), shows ... at an elevated risk of extinction, while 3 species qualify ...
... who reported not taking a daily prenatal vitamin immediately before ... as likely to have a child with an autism spectrum ... the associated risk rose to seven times as great when ... at the UC Davis MIND Institute has found. "Mothers ...
... body against infection don,t huff and puff, but some ... against infection don,t huff and puff, but some of ... steam engine. Weizmann Institute scientists have discovered a mechanism ... when the inflammatory mechanism that protects cells against viruses ...
Cached Biology News:New study provides global analysis of seagrass extinction risk 2Women who start prenatal vitamins early are less likely to have children with autism 2Women who start prenatal vitamins early are less likely to have children with autism 3Women who start prenatal vitamins early are less likely to have children with autism 4Immune system release valve 2
... Taura Syndrome Virus Coat Protein ... tested applications). ... MNDIPITNQN VVLSKNVTDN LFEVQDQALI ESLSRDVLLH NDSWTSSDDE ... terminal amino acids 25/100 of ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
... FastPlax Antibody is used to detect the ... surface of infected cells as early as ... of the FastPlax Titer Kit, which allows ... hours. The FastPlax Antibody can ...
b-Catenin (pSer675), phospho-specific...
Biology Products: